ClinicalTrials.gg
RecruitingNCT07940075Updated Nov 16, 2026

SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .

A Phase 2 interventional study of SYH2062 and Placebo in Mild to Moderate Primary Hypertension, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies in Essential Hypertension with a site in China — 20 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.

Planned enrollment
25th of 67
360 · median 297
Started
2026
with 5 others
Phase 2
7 of 76
1 open now
Primary completion
2027-01
later than 13 of 19 live
Registered
75th of 76
by date

Among the 76 studies in Essential Hypertension with a site in China, this one is the 25th largest by planned enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 13 of the 19 other live ones, and was the 75th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

20 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Essential Hypertension with a site in China, or all of them as a file.
02

Study summary

This phase II clinical trial, involving multiple subcutaneous injections, aimed to evaluate the efficacy, safety, pharmacokinetic (PK), PD, and immunogenicity characteristics of SYH2062 injection in patients with mild to moderate essential hypertension.

03

Conditions studied

  • Mild to Moderate Primary Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age, male or female at the time of signing the ICF;
  • range of 18.0 ≤ BMI ≤ 37.5 kg/m2;
  • Untreated / Currently receiving 1-2 antihypertensive medications;
  • Blood pressure in the clinic during the screening period or before randomization meets 130 ≤ SBP \< 170 mmHg, DBP \< 110 mmHg;
  • Ambulatory blood pressure during the screening period meets 130 mmHg ≤ mSBP;
  • Participants are able to communicate well with the researchers and complete the trial according to the protocol.

Exclusion criteria

Exclusion Criteria:

  • Allergy to any component of the study drug; or a history of severe allergy;
  • Hypertension and secondary hypertension in special populations;
  • History of orthostatic hypotension;
  • Severe cardiovascular or cerebrovascular disease within 6 months prior to screening;
  • History of severe arrhythmia within 6 months prior to screening;
  • Malignant tumor within 5 years prior to screening, except for tumors expected to be curable after treatment (such as completely excised basal cell carcinoma or squamous cell carcinoma of the skin, etc.)
  • Underwent major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period;
  • When screening, and AST > 2 times the , or total and direct bilirubin > 1.5 times the upper limit of normal;
  • Estimated at screening \< 30 mL/min/1.73 m2;
  • Serum potassium level at screening > 5 mmol/L.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    SYH 2062 Injection

    Drug: SYH2062

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSYH2062

    SYH 2062 Injection

  • DrugPlacebo

    Placebo Injection

06

What researchers measure

Primary outcomes

  1. Changes in 24-hour ambulatory blood pressure (mSBP) from baseline at week 12 post-treatment

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

Of 15 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Nov 16, 2026
StartActual
Aug 11, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940075
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Aug 11, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
+8631169085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion